Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations
Oncology · 2024
DOI: 10.1159/000535473 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Oncology, 2024. Verfasst von Marie Mikuteit und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Cell Adhesion Molecules, Kidney Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Nectin-4 is a member of the nectin family and a calcium-independent immunoglobulin-like transmembrane protein that contributes to tumor growth and angiogenesis in malignant tumors. A nectin-4-directed antibody drug conjugate, enfortumab vedotin-ejf, has recently been approved for treatment in urothelial cancer and is currently under investigation in other tumor entities such as breast, lung, and prostate cancer. In non-clear cell renal cell carcinoma (RCC), vascular endothelial growth factor (VEGF)-directed tyrosine kinase inhibitors and checkpoint inhibitors are currently treatments of choice. However, due to the rarity of disease treatment recommendations for chromophobe RCC (chRCC) are limited and new therapeutic agents urgently needed. In this study, we investigated the expression and prognostic impact of nectin-4 in a large cohort of chRCC.
Methods
Patients who underwent renal surgery due to chRCC were recruited. Clinical data were retrospectively evaluated. Tumor specimen was analyzed for nectin-4 expression by immunohistochemistry.
Results
Eighty-one chRCC patients were eligible for analysis. In 15 (18.5%) samples, tumors were positive for nectin-4. No significant associations were found for nectin-4 expression and clinical attributes in patients with chRCC. Kaplan-Meier analysis disclosed a 5-year overall survival for nectin-4-negative and nectin-4-positive tumors of 91.8% versus 100.0% (p = 0.316, log rank).
Conclusions
In chRCC, a small subset of tumors expresses nectin-4 potentially amenable to nectin-4-directed treatment. Expression of nectin-4 is not associated with parameters of aggressiveness or survival. Due to the rare incidence of chRCC, further studies with larger cohorts are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
- Dean's office, Hannover Medical School, Hannover, Germany.
- Department of Medical Oncology, National Center of Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
- Department of Urology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.
- Institute for Pathology and Pathological Anatomy, Technical University Munich, Munich, Germany.
- Member of the German Cancer Consortium (DKTK), Heidelberg, Germany.
Zitieren
APA
Mikuteit, M., Zschäbitz, S., Autenrieth, M., Weichert, W., Hartmann, A., Steffens, S., & Erlmeier, F. (2024). Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations. Oncology. https://doi.org/10.1159/000535473
Vancouver
Mikuteit M, Zschäbitz S, Autenrieth M, Weichert W, Hartmann A, Steffens S, et al. Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations. Oncology. 2024. doi:10.1159/000535473
BibTeX
@article{Mikuteit2024,
author = {Mikuteit, Marie and Zschäbitz, Stefanie and Autenrieth, Michael and Weichert, Wilko and Hartmann, Arndt and Steffens, Sandra and Erlmeier, Franziska},
title = {Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations},
journal = {Oncology},
year = {2024},
doi = {10.1159/000535473}
}
EUVIMED